ArticleOncoTargets and therapy2025

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study.

Hirokazu Iso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.